CME credits were approved by the Mercer Medical School

Cancer Biology and Immunotherapy

Savannah, Georgia | March 30-April 01, 2020
Venue: The DeSoto Savannah | Savannah, GA 31401, USA

Register Abstract

Cancer Biology and Immunotherapy

Savannah, Georgia | March 30-April 01, 2020
Venue: The DeSoto Savannah | Savannah, GA 31401, USA

Register Abstract

Cancer Biology and Immunotherapy

Savannah, Georgia | March 30-April 01, 2020
Venue: The DeSoto Savannah | Savannah, GA 31401, USA

Register Abstract

Organizing Committee

Plenary Speakers

About Janus

JanusJanus was the Roman god of beginnings and transitions. It is depicted as a two-faced image that looks to the future and the past. As first pointed out by Dr. Olivera Finn, the Janus principle can be used to illustrate the past accomplishments and future opportunities in Immunotherapy of Cancer. In this case, immune function/tumor rejection and immune dysfunction/tumor progression. Ann Oncol 2012 Sep 23 (Suppl 8).

About CBI-2020

To date, the passive immunotherapeutic approaches which have been FDA-approved clearly provide clinical benefit to a proportion of advanced disease patients. While these treatments have been heralded as much needed improvements, the nearly 600,000 Americans who died of cancer last year did not gain the level of benefit we would have hoped from modern cancer care. As the frontiers of cancer immunotherapy are pushing forward, we need to concentrate on integrative translational medicine. We are proposing to have an outlet for a comprehensive discussion, which will simultaneously integrate a deep understanding of the biology of cancer along with the development of future treatment concepts to ultimately realize the full potential of this clinical revolution.

Learn more
about image
CBI-2020

Meeting Topics

Cancer Pathology, tumor growth kinetics

Cancer Metastasis

Genomic Heterogeneity

  • Among different patients
  • Within Primary tumors
  • Among cells that metastasize
  • Within metastatic lesions

Passive Immunotherapy

  • Checkpoint inhibitors
  • CAR-T
  • Tumor infiltrating lymphocytes
  • Monoclonal Antibodies
  • Laboratory and Industry production

Immunotherapy beyond Checkpoint Inhibitors

Host-Tumor Interactions

Cancer Vaccines: Design and medical translation

Active Specific Immunotherapy

  • Patient selection for clinical trials: Advanced, Occult disease
  • Adjuvants, development of biocompatible delivery systems
  • Vaccine design and production technology
  • Neoproteins and neoepitopes

Cancer treatment monitoring and drug design

Cancer Prevention

  • Status Australian trials of HPV vaccine for Cervical Cancer

Early Bird

Academic/Federal

$ 500

  • Conference material
  • Access to exhibits, poster sessions
  • Free access to conference app
  • Lunch, tea/coffee breaks
  • WiFi in meeting rooms
Register

Industry/Company

$ 600

  • Conference material
  • Access to exhibits, poster sessions
  • Free access to conference app
  • Lunch, tea/coffee breaks
  • WiFi in meeting rooms
Register

Delegate

$ 700

  • Conference material
  • Access to exhibits, poster sessions
  • Free access to conference app
  • Lunch, tea/coffee breaks
  • WiFi in meeting rooms
Register